Levin Capital Strategies L.P. increased its stake in shares of Fluidigm Co. (NASDAQ:FLDM) by 0.6% during the first quarter, according to its most recent filing with the SEC. The fund owned 5,789,282 shares of the medical research company’s stock after buying an additional 33,529 shares during the period. Levin Capital Strategies L.P. owned 19.80% of Fluidigm worth $32,941,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. bought a new position in shares of Fluidigm during the fourth quarter valued at $16,144,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Fluidigm during the third quarter valued at $4,808,000. Norges Bank bought a new position in shares of Fluidigm during the fourth quarter valued at $1,196,000. FMR LLC bought a new position in shares of Fluidigm during the fourth quarter valued at $1,165,000. Finally, Intellectus Partners LLC bought a new position in shares of Fluidigm during the fourth quarter valued at $988,000.
Fluidigm Co. (NASDAQ:FLDM) traded down 0.55% during midday trading on Friday, hitting $5.46. The stock had a trading volume of 100,068 shares. The firm’s market cap is $159.95 million. Fluidigm Co. has a 52 week low of $4.31 and a 52 week high of $11.05. The firm has a 50 day moving average of $5.20 and a 200 day moving average of $6.10.
COPYRIGHT VIOLATION WARNING: “Fluidigm Co. (FLDM) Position Raised by Levin Capital Strategies L.P.” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://transcriptdaily.com/2017/05/20/fluidigm-co-fldm-position-raised-by-levin-capital-strategies-l-p.html.
FLDM has been the topic of several recent analyst reports. Zacks Investment Research cut Fluidigm from a “buy” rating to a “hold” rating in a research note on Monday, April 10th. Cantor Fitzgerald set a $9.00 price objective on Fluidigm and gave the company a “buy” rating in a research note on Thursday, February 9th.
In related news, Director Samuel D. Colella bought 7,500 shares of the business’s stock in a transaction dated Tuesday, May 9th. The shares were purchased at an average cost of $5.93 per share, with a total value of $44,475.00. Following the completion of the purchase, the director now owns 43,523 shares in the company, valued at approximately $258,091.39. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Samuel D. Colella bought 10,000 shares of the business’s stock in a transaction dated Tuesday, March 14th. The stock was bought at an average cost of $5.00 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the director now owns 43,523 shares of the company’s stock, valued at approximately $217,615. The disclosure for this purchase can be found here. Corporate insiders own 4.50% of the company’s stock.
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Co. and related companies with MarketBeat.com's FREE daily email newsletter.